Thin Film Freezing Technology Co-Inventor Dr.
Members of Dr. Williams’ Lab at The
Research Showcases Versatility and Differentiation of the Thin Film Freezing Technology Platform and its Potential to Address Multiple Challenges in Drug Development of Biologics
Robert O. (Bill) Williams III, Ph.D., co-inventor of Thin Film Freezing technology and special advisor to
One of the five posters, which explores the use of machine learning algorithms (artificial intelligence) to analyze how Thin Film Freezing impacts aerosol delivery of dry powder therapies, will be recognized at the “Poster on the Podium” session to be held on
“We are excited to share these data showcasing the incredible versatility of the Thin Film Freezing platform at the RDD conference,” said
Additionally,
Using E. coli as a model, whose viability in dry powders is highly sensitive to the water content, the research shows that the drying rate of Thin Film Freezing is significantly higher than that of conventional shelf freeze-drying. The research also notes that Thin Film Freezing can be applied to produce dry powders of E. coli and L. acidophilus with minimum bacterial viability loss, and that L. acidophilus dry powder is suitable for intranasal delivery.
RDD 2022 Presentation Details
| Title: | Pivoting Research to Fight COVID-19: Stabilizing and Delivering Antivirals, Antibodies and Vaccines using Thin Film Freezing (Oral Platform Presentation) |
| Date/Time: |
|
| Session: SESSION 1: Focus on Therapeutics: New Tools, Therapies & Technologies | |
| Presenter: Robert O. Williams III |
| Title: | The Applications of Artificial Intelligence in Designing Dry Powder for Inhalation Using Thin-Film-Freezing Technology (Selected for “Poster on the Podium” Presentation) |
| Date/Time: |
|
| Presenters: Junhuang Jiang, |
| Title: | Niclosamide Dry Powder for Inhalation Prepared by Thin Film Freezing Technology Is Effective Against the COVID-19 Infection in the Golden Syrian Hamster Model. |
| Date/Time: |
|
| Presenters: |
| Title: | Aggregation of Lactoferrin Caused by Droplet Atomization Process via Two-fluid Nozzle: the Detrimental Effect of Air-water Interfaces |
| Date/Time: |
|
| Presenters: |
| Title: | Correlation of Specific Surface Area with |
| Date/Time: |
|
| Presenters: Tuangrat Praphawatvet, |
| Title: | Aerosolizable Plasmid DNA Dry Powder Formulations Engineered by Thin-Film Freeze-Drying |
| Date/Time: |
|
| Presenters: |
|
More information on the data being presented at the meeting can be found on the conference website.
About Respiratory Drug Delivery®
Respiratory Drug Delivery, RDD®, addresses emerging issues surrounding drug delivery to the lung and nose. Conferences held in
ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING TECHNOLOGY PLATFORM
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
ABOUT TFF PHARMACEUTICALS
SAFE HARBOR
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the advantages of the Company’s Thin Film Freezing technology over conventional freeze-drying techniques and expectations for its continued development of Inhaled Tacrolimus and Voriconazole Powders, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully commercialize the perceived advantages of the Company’s Thin Film Freezing technology over conventional freeze-drying techniques, (ii) successfully conclude clinical testing or obtain pre-market approval of its Inhaled Tacrolimus or Voriconazole Powders or any of its dry powder product candidates, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (v) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s 2021 Annual Report on Form 10-K filed with the SEC on March 24, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Relations Contact:
(212) 915-2577
cdavis@lifesciadvisors.com
Media Contact:
(269) 921-3607
gschanker@lifescicomms.com
Source: TFF Pharmaceuticals, Inc.